Share on StockTwits

Eli Lilly and (NYSE:LLY) was the target of some unusual options trading on Tuesday. Stock investors purchased 4,883 call options on the stock, StockRatingsNetwork reports. This represents an increase of 182% compared to the typical volume of 1,733 call options.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc unloaded 250,000 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $63.03, for a total value of $15,757,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Several analysts have recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Eli Lilly and from $65.00 to $61.00 in a research note on Monday. They now have a “hold” rating on the stock. Separately, analysts at S&P Equity Research initiated coverage on shares of Eli Lilly and in a research note on Friday, August 1st. They set a “buy” rating on the stock. Finally, analysts at Morgan Stanley raised their price target on shares of Eli Lilly and from $48.00 to $60.00 in a research note on Friday, August 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and a consensus target price of $63.86.

Eli Lilly and (NYSE:LLY) traded up 0.47% on Tuesday, hitting $61.37. The stock had a trading volume of 3,481,525 shares. Eli Lilly and has a one year low of $47.53 and a one year high of $65.70. The stock has a 50-day moving average of $62.49 and a 200-day moving average of $59.25. The company has a market cap of $65.770 billion and a price-to-earnings ratio of 19.40.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.65 by $0.03. The company had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.88 billion. During the same quarter in the prior year, the company posted $1.16 earnings per share. The company’s quarterly revenue was down 16.8% on a year-over-year basis. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.